Bovine Tuberculosis (bTB) roadmap:
Vaccines
Roadmap for the development of candidate vaccine for bTB
Download bTB-Vaccine-Roadmap
---
config:
theme: default
defaultRenderer: 'elk'
themeVariables:
lineColor: "red"
---
flowchart LR
21772["
2
Naturally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine4
Inactivated Vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine7
Vectored vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
1
Vaccine8
Attenuated organisms3
Rationally attenuated candidates- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
8
Attenuated organisms9
Adjuvant9
Adjuvant4
Inactivated Vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant5
DNA/RNA vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
9
Adjuvant6
Subunit vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
10
Expression system9
Adjuvant11
Vector7
Vectored vaccines- ASafety
- BDelivery route
- CDelivery platform
- DEfficacy in challenge model
12
Identity of protective antigens9
Adjuvant12
Identity of protective antigens10
Expression system12
Identity of protective antigens11
Vector13
Identity of virulence factors8
Attenuated organisms13
Identity of virulence factors12
Identity of protective antigens14
Identity of immunomodulators8
Attenuated organisms14
Identity of immunomodulators12
Identity of protective antigens15
Host responses to natural infection8
Attenuated organisms15
Host responses to natural infection12
Identity of protective antigens16
Identity of mechanisms of protection- AAntibody response
- BCell mediated immunity
12
Identity of protective antigens17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence clearance
13
Identity of virulence factors17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence clearance
14
Identity of immunomodulators17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence clearance
15
Host responses to natural infection17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence clearance
16
Identity of mechanisms of protection- AAntibody response
- BCell mediated immunity
18
Pathogen genome17
Host-pathogen interactions- AEntry
- BReplication
- CPersistence clearance
18
Pathogen genome16
Identity of mechanisms of protection- AAntibody response
- BCell mediated immunity
Lead Summary | Challenges and gap analysis | |
---|---|---|
1 | Vaccine | bTb vaccine |
2D | Efficacy in challenge model | Validation of BCG efficacy |
2C | Delivery platform | |
2B | Delivery route | |
2A | Safety | |
2 | Naturally attenuated candidates | |
3D | Efficacy in challenge model | |
3C | Delivery platform | |
3B | Delivery route | |
3A | Safety | |
3 | Rationally attenuated candidates | Development of a novel attenuated vaccine allowing DIVA |
4D | Efficacy in challenge model | |
4C | Delivery platform | |
4B | Delivery route | |
4A | Safety | |
4 | Inactivated Vaccines | |
5D | Efficacy in challenge model | |
5C | Delivery platform | |
5B | Delivery route | |
5A | Safety | |
5 | DNA/RNA vaccines | Development of a DNA vaccine for bovine TB |
6D | Efficacy in challenge model | |
6C | Delivery platform | |
6B | Delivery route | |
6A | Safety | |
6 | Subunit vaccines | Development of a bovine TB subunit vaccine |
7D | Efficacy in challenge model | |
7C | Delivery platform | |
7B | Delivery route | |
7A | Safety | |
7 | Vectored vaccines | Development of a vectored bovine TB vaccine |
8 | Attenuated organisms | Genetically modified M bovis |
9 | Adjuvant | Identifying suitable delivery systems for subunit vaccine candidates and DNA vaccine candidates |
10 | Expression system | |
11 | Vector | Identifying suitable vector for the expression/delivery of protective Antigens |
12 | Identity of protective antigens | Establishing the identity of protective antigens of M bovis |
13 | Identity of virulence factors | Identification of the M bovis virulence factors that contribute to disease pathology |
14 | Identity of immunomodulators | To establish the identity of the immunomodulatory factors and stealth mechanisms operating in M bovis infections |
15 | Host responses to natural infection | Identification of the M bovis immunogens responsible for skin sensitisation to PPD |
16B | Cell mediated immunity | |
16A | Antibody response | |
16 | Identity of mechanisms of protection | To identify protective mechanisms in M bovis infected animals |
17C | Persistence clearance | |
17B | Replication | |
17A | Entry | |
17 | Host-pathogen interactions | Host Pathogen interaction in M bovis infection |
18 | Pathogen genome |